Figure 1.
![MRD status according to cytogenetic risk in the PETHEMA/GEM2012MENOS65 clinical trial. (A) Design of the study, including prespecified time points for prospective evaluation of CAs by FISH and MRD. BUMEL, busulfan-melphalan; I, ixazomib; MEL, melphalan; VRD, bortezomib, lenalidomide, dexamethasone. (B) Rates of persistent and undetectable MRD in patients with standard- vs high-risk CAs [t(4;14), t(14;16), and/or del(17p13)]. Patients with persistent MRD were grouped according to the logarithmic range of detectable MRD (ie, ≥2 × 10−6 to <10−5, ≥10−5 to <10−4, and ≥10−4). *P = .04, by 2-sided χ2 test.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/137/1/10.1182_blood.2020006731/1/bloodbld2020006731f1.png?Expires=1743072496&Signature=gEzX0O~Q0dfHepM2-KkHzWbHEe3pIv8foQzO7heAviqsegvHvi6r2ZJ~~~173f~ooQ9fcB9jhiTwNVemroxbiZkrtslpDHSiORLMLXJvIuM-SzC27TIP0tfxrw1~GYYr2cmDC73NMFybCIn33sgSpc6y2KYywRSrdRSRL3fynaGIWTNTr9Hca8YqF-VGG8teRlpSop32Q9siQPCfRl0wF4tKKt88ASnrs9HDHhsZX3bOidu2QOjdr7Q~VP7a7XTrYdDnM-zaga7tPK583BgfdlAQz~FT4XoIdtZK4SJVs-ho5gj-~JseI5xsnWZ3hyKkGqnXXUbQEDRW8eqaTkotvA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
MRD status according to cytogenetic risk in the PETHEMA/GEM2012MENOS65 clinical trial. (A) Design of the study, including prespecified time points for prospective evaluation of CAs by FISH and MRD. BUMEL, busulfan-melphalan; I, ixazomib; MEL, melphalan; VRD, bortezomib, lenalidomide, dexamethasone. (B) Rates of persistent and undetectable MRD in patients with standard- vs high-risk CAs [t(4;14), t(14;16), and/or del(17p13)]. Patients with persistent MRD were grouped according to the logarithmic range of detectable MRD (ie, ≥2 × 10−6 to <10−5, ≥10−5 to <10−4, and ≥10−4). *P = .04, by 2-sided χ2 test.